3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $260M | -$13M | 65.7% | -4.6% | $17M | $0 | $222M |
| 2024 | $170M | -$47M | 60.6% | -25.7% | -$35M | $30M | $76M |
| 2023 | $123M | -$68M | 57.0% | -53.8% | -$50M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $78M | -$3M | 62.4% | -6.1% | -$12M | — | $212M |
| Dec '25 | $76M | $5M | 70.8% | 4.3% | $21M | $0 | $222M |
| Sep '25 | $68M | -$3M | 66.3% | -3.7% | $10M | $0 | $199M |
| Jun '25 | $61M | -$5M | 65.7% | -7.1% | — | $30M | $223M |
| Mar '25 | $55M | -$9M | 58.0% | -15.3% | -$16M | — | — |
| Dec '24 | $48M | -$8M | 67.0% | -14.8% | -$7M | $30M | $76M |
| Sep '24 | $46M | -$9M | 62.8% | -18.7% | $980000 | — | — |
| Jun '24 | $41M | -$11M | 60.3% | -24.4% | — | — | — |
| Mar '24 | — | -$19M | — | — | — | — | — |
How the market has priced OMDA against its own fundamentals since 2025-06 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Omada Health, Inc.'s revenue has grown 45.6% per year. These are computed facts, not advice.
As of FY2025, Omada Health, Inc. reported $0 of total debt against $222M of cash; operating income covered interest expense -4.7×.
In FY2025, gross margin was 65.7%, operating margin -4.6%, and net margin -4.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.